Armstrong, A. J., Saad, F., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Mehra, N., … Clarke, N. (2022). 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. In Annals of Oncology (Vol. 33, pp. S1168–S1168). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1502

Armstrong, A. J., F. Saad, A. Thiery-Vuillemin, M. Oya, N. D. Shore, N. Mehra, M. Ozguroglu, et al. “1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial.” In Annals of Oncology, 33:S1168–S1168. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1502.

Armstrong AJ, Saad F, Thiery-Vuillemin A, Oya M, Shore ND, Mehra N, et al. 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. In: Annals of Oncology. Elsevier BV; 2022. p. S1168–S1168.

Armstrong, A. J., et al. “1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1168–S1168. Crossref, doi:10.1016/j.annonc.2022.07.1502.

Armstrong AJ, Saad F, Thiery-Vuillemin A, Oya M, Shore ND, Mehra N, Ozguroglu M, Gedye C, Sartor O, Poehlein CH, Qiu P, Liu Y-Z, Riva L, Harrington L, Barker L, Del Rosario PMD, Barnicle A, Clarke N. 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Annals of Oncology. Elsevier BV; 2022. p. S1168–S1168.